Ask Dr James: What can I do about my restless legs?
Just over five years ago I was diagnosed with restless legs syndrome – my symptoms were apparently ‘typical’. The neurologist ...
PharmiWeb1d
Global Parkinson’s Disease Market Set for USD 6.7 Billion Valuation, Powered by a 5.1% CAGR, from 2024 to 2034
Parkinson’s Disease Therapeutic MarketThe Global Parkinson’s Disease Industry is poised to achieve an estimated worth of USD 5.41 Billion, reflecting a notable increase from the USD 4.82 Billion ...
McKnight's Long-Term Care News3d
A new treatment option gets FDA approval for adults with advanced Parkinson’s disease
The US Food and Drug Administration has approved VYALEV, a groundbreaking therapy developed by AbbVie to treat adults with ...
Pharmabiz3d
AbbVie’s Vyalev receives US FDA approval to treat adults living with advanced Parkinson's disease
North Chicago, Illinois Saturday, October 19, 2024, 12:00 Hrs [IST] ...
FDA Approves AbbVie's VYALEV as First 24-Hour Levodopa Infusion for Advanced Parkinson's
The first levodopa-based treatment for motor fluctuations in people with advanced Parkinson's disease, VYALEVa subcutaneous ...
Medscape4d
FDA OKs Novel Levodopa-Based Continuous Sub-Q Regimen for Parkinson’s
Vyalev (AbbVie) is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy to address motor fluctuations in advanced Parkinson’s disease.
AbbVie Secures FDA Approval for Parkinson's Disease Drug Vyalev
With the latest approval, ABBV's Vyalev becomes the first and only subcutaneous 24-hour infusion of levodopa-based therapy ...
The Pharma Letter4d
FDA finally approves Vyalev for Parkinson’s disease
After a couple of negative decisions, the US Food and Drug Administration (FDA) has approved Vyalev (foscarbidopa and ...
pharmaphorum4d
AbbVie gets continuous Parkinson's drug over the line in US
AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator ...
Pharmaceutical Technology4d
FDA approves AbbVie’s VYALEV for advanced Parkinson’s treatment
The US FDA has approved AbbVie's VYALEV to treat motor fluctuations in adults with advanced Parkinson's disease (PD).
BioWorld4d
After delays, Abbvie wins FDA approval for Parkinson’s treatment
With two complete response letters in the rearview mirror, Abbvie Inc.’s Vyalev (foscarbidopa/foslevodopa) has been approved by the U.S. FDA for treating Parkinson’s disease. The drug is the first ...
FDA Approves AbbVie's Parkinson's Treatment, Medicare Coverage Expected Next Year
Vyalev (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for motor ...